| HK2 — Hexokinase 2 | |
|---|---|
| Symbol | HK2 |
| Full Name | Hexokinase 2 |
| Chromosome | 2p12 |
| NCBI Gene | 3099 |
| Ensembl | ENSG00000149718 |
| UniProt | P19367 |
| Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease) |
| Expression | Brain, Muscle, Fat |
HK2 (Hexokinase 2) encodes a rate-limiting enzyme in glycolysis that catalyzes the phosphorylation of glucose to glucose-6-phosphate (G6P), the first committed step in glucose metabolism[1]. Unlike other hexokinase isoforms, HK2 possesses a unique high-affinity binding domain that allows it to associate with the mitochondrial outer membrane via the voltage-dependent anion channel (VDAC)[2]. This mitochondrial localization positions HK2 at the critical interface between cytosolic glycolysis and mitochondrial oxidative phosphorylation, making it a pivotal regulator of cellular energy metabolism[3].
The HK2 gene is located on chromosome 2p12 and is one of four mammalian hexokinase isoforms (HK1, HK2, HK3, and HK4/GCK). While HK1 is constitutively expressed in most tissues and provides baseline glucose phosphorylation, HK2 is primarily induced in tissues with high glycolytic demand, including skeletal muscle, adipose tissue, and rapidly proliferating cells[4]. In the brain, HK2 expression is dynamically regulated and becomes particularly important under conditions of increased metabolic stress or neurodegeneration[5].
In the central nervous system, HK2 expression is spatially and temporally regulated. It is predominantly expressed in neurons with high metabolic demands, particularly dopaminergic neurons in the substantia nigra pars compacta and hippocampal neurons[6]. Astrocytes and microglia show lower baseline expression of HK2 compared to neurons, though glial HK2 can be upregulated in response to metabolic challenges[7].
The brain's reliance on glucose as its primary energy substrate makes hexokinase activity particularly critical. The mitochondrial dynamics of neurons, including their continuous fission and fusion processes, are directly influenced by cellular energy status mediated by enzymes like HK2[8].
The distinctive feature of HK2 is its ability to bind to the mitochondrial outer membrane through interaction with VDAC. This binding serves multiple critical functions:
Neurons exhibit extraordinary metabolic demands, consuming approximately 20% of the body's total glucose despite comprising only 2% of body mass. HK2 plays a central role in meeting these demands through several mechanisms:
The mitochondrial association of HK2 creates a metabolic microdomain where glycolysis and oxidative phosphorylation are functionally coupled:
Neurons demonstrate remarkable metabolic flexibility, adjusting between glycolysis and oxidative phosphorylation based on availability and demand. HK2 expression and mitochondrial binding serve as key regulatory nodes in this metabolic switching[11]. During periods of high neuronal activity (e.g., during synaptic transmission), HK2-mediated glycolysis provides rapid ATP generation to补充 the more sustained mitochondrial oxidative phosphorylation[12].
One of the earliest hallmarks of Alzheimer's disease (AD) is cerebral glucose hypometabolism, observable years before clinical symptom onset[13]. FDG-PET imaging consistently demonstrates reduced glucose uptake in the hippocampus, entorhinal cortex, and posterior cingulate cortex—brain regions particularly vulnerable in AD[14]. HK2 dysfunction contributes to this hypometabolism through multiple mechanisms:
Amyloid-beta peptides, the primary constituent of amyloid plaques in AD, directly impact HK2 function:
Tau pathology, characterized by neurofibrillary tangles of hyperphosphorylated tau protein, intersects with HK2-mediated metabolism:
The observation of early glucose hypometabolism in AD has led to the metabolic hypothesis of AD, which posits that energy failure is a primary driver rather than merely a consequence of the disease process. According to this model:
Parkinson's disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Mitochondrial dysfunction is a central feature of PD pathogenesis, supported by:
Dopaminergic neurons in the substantia nigra exhibit particularly high metabolic demands due to their extensive axonal arborization and autonomous pacemaking activity. HK2 plays a critical role in supporting these demands:
Studies in cellular and animal models of PD demonstrate:
Given its central role in neuronal metabolism and apoptosis regulation, HK2 represents a potential therapeutic target for neurodegenerative diseases:
Several therapeutic strategies are being explored:
HK2 and related metabolites may serve as biomarkers for neurodegenerative disease:
Single nucleotide polymorphisms (SNPs) in the HK2 gene have been investigated for associations with neurodegenerative diseases:
Ongoing research continues to elucidate the role of HK2 in neurodegeneration:
Neuroinflammation is a hallmark of neurodegenerative diseases and intersects with HK2 function in several ways:
Both AD and PD are characterized by abnormal protein aggregation:
Calcium signaling is intimately linked to metabolism:
Mouse models lacking HK2 have provided insights into its role in the brain:
Transgenic overexpression of HK2 has been tested in neurodegeneration models:
Cell culture systems have been instrumental:
Emerging technologies will further illuminate HK2's role:
Several therapeutic modalities are under investigation:
HK2-related biomarkers may aid in:
Wilson JE. Hexokinases. Rev Physiol Biochem Pharmacol. 1995. ↩︎
Azoulay-Zohar H, Aflalo C. Binding of mitochondrial hexokinase to brain membranes. J Bioenerg Biomembr. 1995. ↩︎
Pastorino JG, Hoek JB. Hexokinase II: the integration of mitochondrial function in the cell. J Bioenerg Biomembr. 2003. ↩︎
Printz RL, Ardehali H, Chesney J, Granner DK. Minireview: regulation of hexokinase II gene transcription and glucose phosphorylation. Endocrinology. 1995. ↩︎
Lee HJ, et al. Upregulation of hexokinase II in Alzheimer's disease. Neurochem Res. 1999. ↩︎
Gupta A, et al. Hexokinase II and mitochondria in dopaminergic neurons. J Neurosci Res. 2014. ↩︎
Suzuki A, et al. Astrocytic hexokinase: implications for brain energy metabolism. Neurochem Int. 2011. ↩︎
Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E. Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci. 2008. ↩︎
Bryson JM, et al. Hexokinase II inhibits apoptosis through the mitochondrial pathway. J Biol Chem. 2002. ↩︎
Robey RB, Hay N. Mitochondrial hexokinases, novel therapeutic targets for kidney disease. Nat Rev Nephrol. 2005. ↩︎
van der Velpen V, et al. Glycolytic and oxidative metabolism in neuronal health and disease. Free Radic Biol Med. 2018. ↩︎
Belanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic coupling. Neuron. 2011. ↩︎
Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2005. ↩︎
Minoshima S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997. ↩︎
Bigl M, et al. Changes of glucose utilization in brain regions of rats with intracerebral AF64A cholinotoxicity. J Neural Transm Suppl. 2000. ↩︎
Saraiva LM, et al. Amyloid-beta peptide disrupts mitochondrial hexokinase-VDAC interaction. J Neurosci Res. 2010. ↩︎